Orion and Criceto Announce a License Agreement for APORON®, an Innovative Apomorphine Spray to Treat OFF Episodes in Parkinson’s Disease

Core Insights - Orion Corporation and Criceto IKM B.V. have signed an exclusive license agreement for the development and commercialization of APORON®, an innovative apomorphine oromucosal spray aimed at treating OFF episodes in Parkinson's disease patients [1][2][3] Company Overview - Orion Corporation is a Nordic pharmaceutical company with over a hundred years of experience, focusing on developing, manufacturing, and marketing human and veterinary pharmaceuticals, as well as active pharmaceutical ingredients [5] - In 2024, Orion's net sales reached EUR 1,542 million, and the company employed approximately 3,700 professionals globally [5] Product Development - APORON® is currently in Phase 3 development by Criceto and is designed as a rescue treatment for OFF episodes, which significantly affect the quality of life for Parkinson's disease patients [1][2][4] - The partnership aims to leverage Criceto's expertise in advanced rescue treatments for Parkinson's disease, with the goal of making APORON® a first-line treatment option [3][4] Financial Terms of the Agreement - Under the agreement, Criceto will receive upfront payments, reimbursements for development costs, and royalties on future commercial sales of APORON® [2][3]